α-硫辛酸联合丁咯地尔治疗糖尿病周围神经病变的临床研究

Efficavy and Safety of A-Lipoic Acid Combined with Buflomedil in the treatment of Diabetic Peripheral Nearopathy

目的：评价α-硫辛酸联合丁咯地尔治疗糖尿病周围神经病变的临床疗效、安全性。方法：57例2型糖尿病并发周围神经病变（DPN）患者随机分为两组。治疗组（n=30）静脉给予α-硫辛酸600mg联合丁咯地尔200mg，1a／d，连续14d；对照组（n=27）静脉给予α-硫辛酸600mg联合前列地尔10pg，1次／d，连续14d。分别于用药前、用药7d、14d进行多伦多临床神经病变评分（TCss）和神经病变主觉症状评分（TSS），并记录其不良反应。结果：两组在治疗7d时，TCSS、TSS评分均开始下降（P0．05）；治疗14天后，TCSS及TSS评分进一步显著降低（P〈0．01）；但治疗后两组间无显著性差异（P〈0．05）。治疗组有1例出现面色潮红；对照组有3例出现静脉炎而停止使用。结论：α-硫辛酸联合丁咯地尔可有效改善2型糖尿病病人的周围神经病变，且副反应少。

Objective To evaluate the efficavy and safety of a-lipoic acid combined with buflomedil in the treatment of Diabetic Peripheral Neuropathy （DPN）. Methods：Sixth T2DM patients with DPN were dived into two groups. The treatment group（n= 30）was intravenously iniected with a-lipoic acid 600mg/d and buflomedil 0.2g/d. The control group （n=27）was intravenously injected with a-lipoic acid 600mg/d and alprostadil 10ug/d. They were all trea- ted once a day for 14 days. Befor and 7 and 14 days after the management,and total symptom score（TSS）were used to evaluate the nervous symptoms and re cord adverse recation. Results： The TCSS and TSS score 7 days after the management of the two groups reduced significantly after 7 days（both P〈0.05）. The TCSS and TSS score 14 days after the management o~ the two groups were significantly lower than that of the two groups 7 days（both P〈0. 01）. But there were no signifant differences between two groups（P〉0.05）. One patient of the treatment group felt flushed face 2 days after treatment,three patient of the control group was found phlebitics and stop treatment. Conclusion：A-lipoic acid combined with alprostadil effectively improves the sensitive symptoms of DPN patients and is safe for most of the patients.